GLP-1 Medications Show No Clear Harm to Male Fertility, May Offer Indirect Benefits
Current evidence suggests that GLP-1 receptor agonist medications, such as Ozempic, Wegovy (semaglutide), and Mounjaro (tirzepatide), do not clearly harm male fertility. While official product information for semaglutide states that its effect on human fertility is unknown due to limited human data, animal studies have not shown adverse effects on male fertility. In fact, early research indicates that these medications may indirectly improve certain reproductive markers in men, particularly those with obesity-related metabolic or hormonal issues. Studies have reported potential improvements in testosterone levels and sperm quality, including morphology, in obese men with type 2 diabetes. These benefits are largely attributed to the overall improvement in metabolic health and weight loss achieved with GLP-1 treatments, rather than a direct action on sperm production.